These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15370278)

  • 1. Safety and ethical consideration of AIDS vaccine.
    Veljkovic V; Prljic J; Veljkovic T
    Int Rev Immunol; 2004; 23(5-6):465-86. PubMed ID: 15370278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIDS vaccine: efficacy, safety and ethics.
    Veljkovic V; Veljkovic N; Glisic S; Ho MW
    Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombination property of the HIV-1 gp120 gene.
    Prljic J; Veljkovic N; Veljkovic V
    Int Rev Immunol; 2004; 23(5-6):447-54. PubMed ID: 15370276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network.
    Keefer MC; Belshe R; Graham B; McElrath J; Clements ML; Sposto R; Fast P
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S139-40. PubMed ID: 7865288
    [No Abstract]   [Full Text] [Related]  

  • 7. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 gp120 and immune network.
    Metlas R; Veljkovic V
    Int Rev Immunol; 2004; 23(5-6):413-22. PubMed ID: 15370273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine adds more proteins to enhance effectiveness.
    AIDS Patient Care STDS; 1996 Jun; 10(3):189. PubMed ID: 11361637
    [No Abstract]   [Full Text] [Related]  

  • 10. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.
    Maksyutov AZ; Bachinskii AG; Bazhan SI; Ryzhikov EA; Maksyutov ZA
    J Clin Virol; 2004 Dec; 31 Suppl 1():S26-38. PubMed ID: 15567091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from failure--preparing for future HIV-1 vaccine efficacy trials.
    Graham BS; Mascola JR
    J Infect Dis; 2005 Mar; 191(5):647-9. PubMed ID: 15688276
    [No Abstract]   [Full Text] [Related]  

  • 14. AIDSVAX is safe, but efficacy question remains. VaxGen founder discusses quest for AIDS vaccine.
    Francis DP
    AIDS Alert; 2001 Nov; 16(11):141-2, 147. PubMed ID: 11692665
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
    McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
    AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits.
    Pal R; Yu Q; Wang S; Kalyanaraman VS; Nair BC; Hudacik L; Whitney S; Keen T; Hung CL; Hocker L; Kennedy JS; Markham P; Lu S
    Vaccine; 2006 Feb; 24(8):1225-34. PubMed ID: 16219399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
    Gilbert PB; Peterson ML; Follmann D; Hudgens MG; Francis DP; Gurwith M; Heyward WL; Jobes DV; Popovic V; Self SG; Sinangil F; Burke D; Berman PW
    J Infect Dis; 2005 Mar; 191(5):666-77. PubMed ID: 15688279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus as vector for HIV: efficacy and safety issues.
    Natuk RJ; Wade MS; Chengalvala M; Murthy KK; Chanda PK; Murthy SC; Bhat BM; Bhat R; Dheer SK; Mizutani S
    Dev Biol Stand; 1995; 84():153-6. PubMed ID: 7796948
    [No Abstract]   [Full Text] [Related]  

  • 19. AIDS Vaccine 2005.
    Haigwood NL; Doria-Rose N
    IDrugs; 2005 Nov; 8(11):898-900. PubMed ID: 16254780
    [No Abstract]   [Full Text] [Related]  

  • 20. AIDS/HIV. A STEP into darkness or light?
    Moore JP; Klasse PJ; Dolan MJ; Ahuja SK
    Science; 2008 May; 320(5877):753-5. PubMed ID: 18467578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.